TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28325630

Group type: EXPERIMENTAL
Intervention: Experimental group (patient reluctance mentioned)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (patient reluctance not mentioned)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Evidence Based Practice (EBP) attitudes
Number of subjects: 236
Study: 25640827

Group type: EXPERIMENTAL
Intervention: High-quality foster care
Number of subjects: 102

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Long allele carriers (both groups)
Number of subjects: 102
Study: 24823330

Group type: EXPERIMENTAL
Intervention: Porcine intestinal submucosa (SIS)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Silver-containing cellulose hydrofiber (AgH)
Number of subjects: 5
Study: 21316157

Group type: EXPERIMENTAL
Intervention: Extensive normative feedback (Intervention Group)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Very brief feedback (Control Group)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG)
Number of subjects: 158
Study: 19618688

Group type: EXPERIMENTAL
Intervention: NaFeEDTA fortified wheat flour
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: FeSO4 fortified wheat flour
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Electrolytic iron fortified wheat flour
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-fortified flour (control)
Number of subjects: 400
Study: 17329296

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional antipsychotics (CA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Olanzapine and CA
Number of subjects: 63
Study: 15554315

Group type: EXPERIMENTAL
Intervention: Combined vaccine 'Bubo-Kok'
Number of subjects: 0
Study: 11447364

Group type: EXPERIMENTAL
Intervention: MCT oil (60 g daily for 2 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: LCT (corn oil, 56 g daily for 2 weeks)
Number of subjects: 12
Study: 8694324

Group type: EXPERIMENTAL
Intervention: Alfentanil (3 micrograms/kg increments)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 23
Study: 1306672

Group type: EXPERIMENTAL
Intervention: Colgate Precision toothbrush
Number of subjects: 151

Group type: COMPARATOR
Intervention: Oral-B 40 toothbrush
Number of subjects: 151

Group type: COMPARATOR
Intervention: Reach Full-Head soft toothbrush
Number of subjects: 151
Study: 4009848

Group type: EXPERIMENTAL
Intervention: Unilateral vertebral operations
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Specific operative procedures (subclavian-vertebral roof-patch angioplasty, reimplantation, carotid-vertebral vein bypass, decompression)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Neurologic complications
Number of subjects: 109
Study: 31204328

Group type: EXPERIMENTAL
Intervention: General dental practitioners (GDPs)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Non-practicing molar endodontics
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Referring difficult cases to endodontists
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Vital single visit root canal treatment
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Necrotic single visit root canal treatment
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Standardized preparation technique
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Non-setting calcium hydroxide as intra-canal medicament
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Delaying final restoration
Number of subjects: 188
Study: 29551340

Group type: EXPERIMENTAL
Intervention: Influenza vaccine offered in the intervention group
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no vaccine offered)
Number of subjects: 109
Study: 28163478

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 25048955

Group type: EXPERIMENTAL
Intervention: Nurse-led interventions (follow-up by a specialist nurse after 3 months)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 459
Study: 23013352

Group type: EXPERIMENTAL
Intervention: Curcumin (80 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 19945816

Group type: EXPERIMENTAL
Intervention: Intensive telephone counseling (bi-weekly)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Less intensive telephone counseling (monthly)
Number of subjects: 360
Study: 17643971

Group type: EXPERIMENTAL
Intervention: Central tendency measure (CTM)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: CTM
Number of subjects: 187

Group type: COMPARATOR
Intervention: Classical indexes (ODIs and CT90)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Indexes derived from approximate entropy (ApEn)
Number of subjects: 187
Study: 16097274

Group type: EXPERIMENTAL
Intervention: Reward allocations by kindergartners
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Reward allocations by older participants (3rd grade, 9th grade, college)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Fairness ratings
Number of subjects: 112
Study: 12389338

Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg 3 times a day for 12 days (administered on day 8 before digoxin)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Digoxin 0.75 mg (administered alone)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Simulated steady-state peak levels of digoxin with acarbose
Number of subjects: 11

Group type: COMPARATOR
Intervention: Simulated steady-state peak levels of digoxin without acarbose
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Simulated steady-state trough (Cmin,ss) and average (Cave,ss) concentrations
Number of subjects: 11
Study: 10430713

Group type: EXPERIMENTAL
Intervention: Inhibition of deep inspiration during methacholine challenge
Number of subjects: 10

Group type: COMPARATOR
Intervention: Initial methacholine challenge with DIs
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhibition of deep inspiration after three doses of methacholine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhibition of deep inspiration after four doses of methacholine
Number of subjects: 10
Study: 7556961

Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1347

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1347

Group type: COMPARATOR
Intervention: Intensive treatment
Number of subjects: 1347
Study: 1934686

Group type: EXPERIMENTAL
Intervention: 20 mg of hyaluronic acid administered intra-articularly once a week for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: 40 mg of 6-methylprednisolone acetate administered intra-articularly once a week for 3 weeks
Number of subjects: 0
Study: 6179650

Group type: EXPERIMENTAL
Intervention: Dibromodulcitol 10 mg/kg PO weekly for 8 weeks plus bleomycin 15 mu/m2 (initially three times weekly, later changed to twice weekly for 8 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Bleomycin 15 mu/m2 (initially three times weekly, later changed to twice weekly for 8 weeks)
Number of subjects: 62
Study: 30912836

Group type: EXPERIMENTAL
Intervention: Sustained inflations (up to 2 sustained inflations at maximal peak pressure of 25 cm H2O for 15 seconds); n=215
Number of subjects: 426

Group type: COMPARATOR
Intervention: Standard intermittent positive pressure ventilation; n=211
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Sustained inflations; n=215
Number of subjects: 426
Study: 29417850

Group type: EXPERIMENTAL
Intervention: Ginger root powder (0.5 g, 2 capsules per day, 0.25 g per capsule, every 12 hours for 5 days)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ginger root powder
Number of subjects: 140
Study: 27100399

Group type: EXPERIMENTAL
Intervention: Prebiotic arabinoxylan oligosaccharides (AXOS) 10 g twice daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prebiotic arabinoxylan oligosaccharides (AXOS)
Number of subjects: 39
Study: 24500725

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 489

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 489
Study: 22313047

Group type: EXPERIMENTAL
Intervention: CYP2C8*3 allele
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: CYP2C8*4 allele
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: CYP2C8*2 allele
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: CYP2C8*3 and CYP2C8*4 alleles
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: CYP2C8 variants
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: CYP2C8 variants in the Czech population
Number of subjects: 161
Study: 19398072

Group type: EXPERIMENTAL
Intervention: Aqueous standardised extract of kava
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17985945

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No Hormone Replacement Therapy (Control)
Number of subjects: 15
Study: 14981335

Group type: EXPERIMENTAL
Intervention: High-dose Hypericum perforatum extract WS 5570 (600, 900, and 1,200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11574227

Group type: EXPERIMENTAL
Intervention: Animal models of ischemia and ex vivo reperfusion
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Endothelial measures of outcome
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Clinical transplantation studies
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 249
Study: 9827425

Group type: COMPARATOR
Intervention: Salbutamol (0.5%‐1 cc) every 12 h + Placebo every 12 h
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Furosemide with Salbutamol
Number of subjects: 50
Study: 7816287

Group type: EXPERIMENTAL
Intervention: Angiotensin II (1.25 and 2.5 ng.kg‐1 min‐1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (lithium carbonate 750 mg, 20 mmol)
Number of subjects: 25
Study: 3075724

Group type: EXPERIMENTAL
Intervention: Desipramine 150 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metapramine 450 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study: 30468528

Group type: EXPERIMENTAL
Intervention: Elastic cuff (5 cm wide) applied to one arm at 10% and 20% of resting length
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pressurized nylon cuff (5 cm wide) inflated to 40% and 80% of resting arterial occlusion pressure
Number of subjects: 35
Study: 27309340

Group type: EXPERIMENTAL
Intervention: Structured discharge information
Number of subjects: 3
Study: 25661111

Group type: EXPERIMENTAL
Intervention: Caregiver education level (completed high school)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Children's dental visits
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Caregiver education level
Number of subjects: 423
Study: 23227676

Group type: EXPERIMENTAL
Intervention: Heart-kidney acupuncture group
Number of subjects: 111

Group type: COMPARATOR
Intervention: Conventional acupuncture group
Number of subjects: 111
Study: 20945740

Group type: EXPERIMENTAL
Intervention: Bur-prepared restorations
Number of subjects: 27

Group type: COMPARATOR
Intervention: Laser-prepared restorations
Number of subjects: 27
Study: 17630271

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (CR) programme
Number of subjects: 49

Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation (CR) programme
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: General reasons for non-adherence
Number of subjects: 49
Study: 16131498

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control (non-intervention assessment-only)
Number of subjects: 162
Study: 12362923

Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg once daily with food
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg once daily without food
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study: 11125744

Group type: EXPERIMENTAL
Intervention: Imagined movements of the hand and foot in individuals with paraplegia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagined movements of the hand and foot in individuals with quadriplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imagined movements of the hand and foot in able-bodied controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagined movements of the foot in individuals with paraplegia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagined movements of the foot in individuals with quadriplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imagined movements of the foot in able-bodied controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Movement and imagery ERPs comparison
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagined movements of paralyzed limbs
Number of subjects: 0
Study: 7480677

Group type: EXPERIMENTAL
Intervention: Hepatic arterial phase (HAP) helical CT
Number of subjects: 103

Group type: COMPARATOR
Intervention: Portal venous phase (PVP) helical CT
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dual-phase acquisition
Number of subjects: 103
Study: 2089926

Group type: EXPERIMENTAL
Intervention: Nimodipine (2 mg per hour intravenously for 7 days)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 444345

Group type: EXPERIMENTAL
Intervention: suxamethonium 0.2 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: suxamethonium 0.6 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: suxamethonium 1.0 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: hexafluorenium 0.3 mg kg‐1 with suxamethonium 1.0 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: hexafluorenium 0.3 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: suxamethonium 0.2 mg kg‐1 and 0.6 mg kg‐1 with or without hexafluorenium
Number of subjects: 60
Study: 31406051

Group type: EXPERIMENTAL
Intervention: Sugammadex 1 mg·kg‐1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg·kg‐1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg·kg‐1
Number of subjects: 75
Study: 29547835

Group type: EXPERIMENTAL
Intervention: Tivozanib (1.5 mg/day orally; 3 weeks on/1 week off)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Sorafenib (previous treatment)
Number of subjects: 162
Study: 26803690

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (target, 50mmol/24 h)
Number of subjects: 23
Study: 24690305

Group type: EXPERIMENTAL
Intervention: Family Check-Up condition
Number of subjects: 731
Study: 22642858

Group type: EXPERIMENTAL
Intervention: Broad-spectrum personality traits (positive emotionality, negative emotionality, and constraint) and past-year psychopathology (anxiety, mood, and substance use disorder) as predictors.
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Negative emotionality
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Psychopathology (anxiety, mood, and substance use disorder)
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Substance use disorder and constraint
Number of subjects: 1365

Group type: COMPARATOR
Intervention: No single variable
Number of subjects: 1365
Study: 20502377

Group type: EXPERIMENTAL
Intervention: Titanium prostheses (Ti)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxyapatite prostheses (HA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Titanium and Hydroxyapatite prostheses
Number of subjects: 0
Study: 18397445

Group type: EXPERIMENTAL
Intervention: Chronic Care Model (CCM) for obesity
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 107
Study: 16084809

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapy and cognitive remediation, 50 minutes each, 3 times a week for 11 weeks.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (wait-listed, received treatment after follow-up).
Number of subjects: 20
Study: 12641387

Group type: EXPERIMENTAL
Intervention: New‐RH (S‐group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional therapy (C‐group)
Number of subjects: 16
Study: 10941863

Group type: EXPERIMENTAL
Intervention: Bombesin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bombesin + atropine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bombesin + somatostatin
Number of subjects: 8
Study: 8528637

Group type: COMPARATOR
Intervention: HFX RT to a total dose of 64.8 Gy (Group 1)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: HFX RT with chemotherapy (100 mg carboplatin on days 1 and 2 and 100 mg etoposide on days 1-3 each week during RT) (Group 2)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: HFX RT with chemotherapy (200 mg carboplatin on days 1 and 2 and 100 mg etoposide on days 1-5 of the first, third, and fifth weeks) (Group 3)
Number of subjects: 169
Study: 12283016

Group type: EXPERIMENTAL
Intervention: RU 486 (Mifepristone) 200 mg/day for 2 days before surgery
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 7297145

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dipyridamole (DPY)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of ASA and DPY (ASA-DPY)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30711853

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT)
Number of subjects: 22
Study: 28960867

Group type: EXPERIMENTAL
Intervention: Clinical presentation at first HF hospitalization
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Prior HF hospitalization
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Digitalis therapy
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Left ventricular end‐diastolic volume >240 mL
Number of subjects: 193
Study: 26422331

Group type: EXPERIMENTAL
Intervention: Remote telementored (RTM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unmentored (UTM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Surgeons
Number of subjects: 12
Study: 22964761

Group type: EXPERIMENTAL
Intervention: Initial letter fluency training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phonemic switching training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study: 20864946

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) treatment (5 mg/day for 4 weeks)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Folic acid (FA) treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 18466662

Group type: EXPERIMENTAL
Intervention: Informational session, faxed reporting reminder, and newsletter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 18294107

Group type: EXPERIMENTAL
Intervention: Montelukast 5-10 mg/day for 3-7 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Albuterol (2 puffs of metered-dose inhaler just before exercise challenge)
Number of subjects: 11
Study: 16087295

Group type: EXPERIMENTAL
Intervention: Intradermal capsaicin injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intradermal saline placebo injections
Number of subjects: 20
Study: 12407092

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride solution (44,800 ppm F) applied annually
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride solution (44,800 ppm F) applied annually after removal of soft carious tissues
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Sodium fluoride varnish (22,600 ppm F) applied every three months
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Sodium fluoride varnish (22,600 ppm F) applied every three months after removal of soft carious tissues
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 375
Study: 10092314

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation (12 L/min for 9 hours)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 15
Study: 7602344

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy containing cyclophosphamide
Number of subjects: 2638
Study: 2379530

Group type: EXPERIMENTAL
Intervention: Domperidone (15 mg) followed by Pergolide (25 micrograms) after 1 hour
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo followed by Pergolide (25 micrograms) after 1 hour
Number of subjects: 9

Group type: COMPARATOR
Intervention: Domperidone (15 mg) followed by Placebo after 1 hour
Number of subjects: 9
Study: 373775

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate and bupranolol
Number of subjects: 16
Study: 31981856

Group type: EXPERIMENTAL
Intervention: Serial ketamine infusions
Number of subjects: 50

Group type: COMPARATOR
Intervention: ECT
Number of subjects: 50
Study: 30716917

Group type: EXPERIMENTAL
Intervention: Petit-suisse cheese with Lactobacillus casei
Number of subjects: 0

Group type: COMPARATOR
Intervention: Petit-suisse cheese without Lactobacillus casei (control)
Number of subjects: 0
Study: 28323656

Group type: EXPERIMENTAL
Intervention: Loupe magnification (LM) for tumor margin assessment
Number of subjects: 93

Group type: COMPARATOR
Intervention: Clinical examination alone (control)
Number of subjects: 93
Study: 25599828

Group type: EXPERIMENTAL
Intervention: Basic intervention (tailored intervention targeting individual cognition and self-regulation processes)
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: Plus intervention (basic intervention additionally targeting environmental-level factors)
Number of subjects: 1349

Group type: COMPARATOR
Intervention: Control group (generic nutrition information)
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: Basic intervention (risk groups)
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: Plus intervention (risk groups)
Number of subjects: 1349